Cancer Related Funding Opportunities

Pre-announcements

Dept of Defense - Breast Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)

The Fiscal Year 2021 (FY21) Defense Appropriations Bill has not been signed into law. Although FY21 funds have not been appropriated for the Department of Defense Breast Cancer Research Program (BCRP), the BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.

The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

Subject to the FY21 Congressional appropriation for BCRP funding, FY21 BCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.

Applications submitted to the FY21 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

More Information

Dept of Defense - Melanoma Research Program Preannouncement

Applications submitted to the FY21 MRP must address one or more of the following focus areas:

  • Identify methods to decrease risk of melanoma development beyond sunscreen and protective clothing
  • Identify and understand risk factor determinants for melanoma, including variants (e.g., uveal, acral, mucosal melanoma)
  • Identify how the tumor microenvironment (e.g., stromal, immune, microbiome) impact tumor initiation, response to therapy, progression, and dormancy
  • Understand how precursor lesions and endogenous host factors may lead to melanomagenesis
  • Develop new decision-making tools for the detection and diagnosis of melanoma that include easily accessible technology (beyond the dermoscope) for primary care physicians and dermatologists
  • Develop prediction and surveillance tools for distinguishing patient at risk for recurrence and/or metastasis. Identify biological determinants to differentiate patient populations
  • Understand mechanisms that underlie metastatic spread to different (regional/nodal) sites or the different distant sites of metastasis from acral, mucosal, and uveal melanomas
  • Delineate the molecular pathways, tumor microenvironment, immune response that influence metastatic spread, recurrence, and/or dormancy

More Information

Dept of Defense - Pancreatic Cancer Research Program (PCARP) Pre-Announcement

Applications submitted to the FY21 PCARP must address one or more of the following Focus Areas:

  • Early detection research for pancreatic cancer, including studies of individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities
  • Supportive care and patient-reported outcomes, quality of life, and perspectives during treatment and survivorship
  • Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia
  • Understanding precursors, origins, and early progression of pancreatic cancer
  • Understanding the events that promote pancreatic cancer metastasis
  • Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
  • New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance

More Information

Dept of Defense - Rare Cancers Research Program Preannouncement

Vision Statement
To greatly improve outcomes for people with rare cancer through discovery and community building, and expansion of knowledge across the cancer landscape.

Mission Statement
Elevate rare cancers research to enable clinically impactful discoveries for the benefit of Service Members, their families, Veterans, and the American public. 

Concept Award and Idea Development Award applications submitted to the FY21 RCRP must address one or more of the following Focus Areas:

  • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
  • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
  • Therapy: Identify novel therapeutic strategies, including drug repurposing.

Resource and Community Development Award applications submitted to the FY21 RCRP must address the Focus Areas below:

  • Platform Development: Development of platforms (such as tumor tissue repository with clinical annotation, centralized databanks, patient registry with common data structure, research model and Omics database, longitudinal studies of natural history, and treatment response) for multiple rare cancers, to allow sharing of data, bio-specimens, and resources.

More Information

June 2021 Application Deadlines

06/17/2021 to 09/02/2021 - Dept of Defense - Prostate Cancer Research Program (PCRP)

Awards Include:

  • Early Investigator Research Award – Pre-Application (Letter of Intent): June 17, 2021
  • Physician Research Award – Pre-Application (Letter of Intent): June 17, 2021
  • Translational Science Award – Pre-Application (Letter of Intent): July 15, 2021
  • Health Disparity Research Award – Pre-Application (Letter of Intent): July 15, 2021
  • Data Science Award – Pre-Application (Letter of Intent): July 15, 2021
  • Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award – Pre-Application (Letter of Intent): July 15, 2021
  • Idea Development Award – Pre-Application (Letter of Intent): Sept 2, 2021
  • Clinical Consortium Award – Pre-Application (Letter of Intent): Sept 2, 2021

More Information

06/18/2021 - Alex's Lemonade Stand Foundation Revised Eligibility Criteria for the ALSF ‘A’ Award

Alex’s Lemonade Stand Foundation (ALSF) is pleased to announce that we are now accepting applications for the 2021 ‘A’ Award Grant. The ‘A’ Award is a four-year grant designed for independent, early-career scientists who demonstrate a commitment to pediatric cancer research and have institutional support for their career development. A mentor and career development plan are required. The 3 budget for this award is up to $800,000 USD over four years, and funding will begin in Q1 of 2022.

Application Deadline: June 18, 2021

More Information

06/24/2021 - Dept of Defense - Ovarian Cancer Research Program (OCRP)

Award – Omics Consortium Award

Pre-Application Deadline: June 24, 2021

More Information

06/29/2021 - American Association for Cancer Research: Transformative Cancer Research Grants Program

Deadline: LOI due June 29, 2021

Amount/Duration: $400,000 for two years

Eligibility: Applicants must hold an appointment at the rank of assistant or associate professor at the start of the grant term on December 1, 2021, and work at an academic, medical, or research institution anywhere in the world. There are no citizenship or geographic requirements.

About: The novel grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels, and it is expected that the grants will catalyze significant scientific discoveries that advance the understanding of cancer and have a potentially transformative impact on future clinical practice.

Link: AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants | AACR GrantsMore Information

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

06/30/2021 - Pfizer: Progress in Androgen Deprivation Therapy in Advanced Prostate Cancer

Deadline: June 30, 2021

Amount/Duration: Up to $250,000 for up to two years

Eligibility: Eligible applicants include medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

About: Grants will be awarded in the following general areas of interest: raise awareness of cardiovascular risk in patients with prostate cancer receiving Androgen Deprivation Treatment (ADT); differentiate the clinical significance of LHRH agonists vs. GnRH antagonists; provide multidisciplinary care teams the latest updates on ADT treatment options; and mindfully recognize patient preference and adherence data regarding oral vs. parenteral oncologic therapy.

Link: CGA Template rev Nov 2017 (pfizer.com)

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

July 2021 Application Deadlines

07/01/2021 - Damon Runyon Cancer Research Foundation: Innovative Research Award

Deadline: July 1, 2021

Amount/Duration: $200,000 a year for two years will be awarded, along with an opportunity for up to two additional years of funding (i.e., up to four years for a total of $800,000).

Eligibility: Applicants must be conducting independent research at a U.S. research institution. Applicants must have received an MD, DO, PhD, or MD/PhD degree(s) from an accredited institution.

About: The award will provide funding to extraordinary early-career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. Research supported by the award must be novel, exceptionally creative, and, if successful, have the strong potential for high impact in the cancer field.

Link: Damon Runyon-Rachleff Innovation Award Overview | Damon Runyon

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

07/12/2021 - Alex's Lemonade Stand Foundation 2021 Young Investigator Grant

Alex’s Lemonade Stand Foundation (ALSF) is pleased to announce that we are now accepting applications for the 2021 Young Investigator Grant. The Young Investigator Grant is a mentored career development award designed to support early career researchers, such as postdoctoral fellows, clinical fellows or instructors, striving to develop independent careers in pediatric cancer research. A mentor is required, and a career development plan must be included. The budget for this award is $150,000 over three years, and funding will begin in Q1 of 2022.

Application Deadline: July 12, 2021

More Information

07/16/2021 - Oncomine Clinical Research Grant Program

The Oncomine Clinical Research Grant Program supports education projects & investigator-initiated studies (IIS) on molecular testing in reproductive health & oncology. The goal of the grant program is to increase high-quality molecular profiling for patients and to improve future clinical outcomes.

Application Submission Dates: June 14, 2021 to July 16, 2021

More Information

August 2021 Application Deadlines

08/02/2021 - Emerald Foundation, Inc: Black in Cancer Postdoctoral Fellowship

Deadline: LOI due August 2, 2021

Amount/Duration: $75,000 per year up to three years

About: The goals of this award are to advance innovative strategies that will lead to preventions, treatments, or cures for cancers of all types, promote research into disparities in cancer outcomes in the Black community, and increase Black representation in the cancer research community.

For assistance contact:
Development Office – Corporate and Foundation Relations
honour.harlowe@mountsinai.org
646-605-8715

GCO Funding Opportunities

Monthly and continuous submission funding opportunity packets are available on the GCO Funding Opportunities web page.

STAY CONNECTED

Sign up for the Research Listserv to stay up to date with the latest news and events.